CLT-009

CLT-009 is an investigational, first-in-class, human allogeneic megakaryocyte progenitor cell therapy being developed for the treatment of thrombocytopenia, particularly in settings such as radiation exposure or hematologic injury where platelet counts are severely reduced.[1][2][16] It consists of ex vivo–expanded donor-derived megakaryocyte progenitor cells intended to home to the bone marrow and rapidly generate functional platelets, thereby shortening the duration and severity of thrombocytopenia and reducing the need for platelet transfusions.[1][2] The program has been advanced by Cellerant Therapeutics with SBIR contract funding to enable preclinical development and manufacturing activities.[1][2][10]